Nam et al. demonstrated that mutations reducing KIF5A expression are important in the development of hereditary spastic paraplegia (HSP) and axonal Charcot–Marie–Tooth peripheral neuropathy type 2 (CMT2). This evidence concerns the gene KIF5A and Charcot-Marie-Tooth disease type 2.